The significance of HPV in the follow-up period after treatment for CIN

Purpose of investigation: High-risk anogenital human papillomavirus (HPV) infections are causally related to cervical cancer. Successful treatment of cervical intraepithelial neoplasia (CIN) results in complete eradication of HPV in most cases. There is an increasing interest regarding the role of HPV testing in the follow-up period after treatment for CIN. Patients and Methods: This retrospective study includes 107 women who underwent conization for histologically verified CIN. All of them had HPV testing pre- and postoperatively. HPV testing was carried out using a hybrid capture assay (HC2). The mean follow-up period was 21.4 months (range 2-76 months). The data were analyzed with respect to success of conization, HPV persistence/recurrence and CIN recurrence. Sensitivity, specificity and negative predictive value (NPV) of HPV testing were assessed and compared to the cytological results. Results: Preoperatively, 97 of 107 women were HPV positive. Ninety-seven conizations showed negative resection margins with 86 women becoming HPV negative. In the following months, nine of these HPV negative women became HPV positive again. Out of ten conizations with positive resection margins, six women became HPV negative. Recurrent CIN 2/3 lesions were observed in 11 women, nine of whom had persistent positive HPV testing throughout the entire study period. Regarding CIN recurrence HPV testing showed a sensitivity of 93%, a specificity of 85% and a NPV of 99%. Conclusions: The sensitivity of HPV testing concerning persistent or recurrent CIN as well as the NPV are high. The present data suggest that HPV testing should be integrated in a follow-up algorithm after treatment for CIN by conization.

CIN; Conization; LEEP; Follow-up.

[1] Pisani P., Parkin D.M., Ferlay J.: “Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden”. Int. J. Cancer, 1993, 55, 891.

[2] Parkin D.M., Bray F., Ferlay J., Pisani P.: “Global cancer statistics, 2002”. CA Cancer J. Clin., 2005, 55, 74.

[3] Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V. et al.: “International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer”. N. Engl. J. Med., 2003, 348, 518.

[4] Agnantis N.J., Sotiriadis A., Paraskevaidis E.: “The current status of HPV DNA testing”. Eur. J. Gynaecol. Oncol., 2003, 24, 351.

[5] Wiley D., Masongsong E.: “Human papillomavirus: the burden of infection”. Obstet. Gynecol. Surv., 2006, 61 (6 suppl. 1), S3.

[6] Bekkers R.L., Massuger L.F., Bulten J., Melchers W.J.: “Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer”. Rev. Med. Virol., 2004, 14, 95.

[7] Cox J.T.: “Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management”. Obstet. Gynecol. Surv., 2006, 61 (6 suppl. 1), S15.

[8] Elfgren K., Jacobs M., Walboomers J.M., Meijer C.J., Dillner J.: “Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia”. Obstet. Gynecol., 2002, 100, 965.

[9] Chao A., Lin C.T., Hsueh S., Chou H.H., Chang T.C., Chen M.Y., Lai C.H.: “Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization”. Am. J. Obstet. Gynecol., 2004, 190, 1046.

[10] Paraskevaidis E., Arbyn M., Sotiriadis A., Diakomanolis E., Martin-Hirsch P., Koliopoulos G. et al.: “The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature”. Cancer Treat. Rev., 2004, 30, 205.

[11] Zielinski G.D., Bais A.G., Helmerhorst T.J., Verheijen R.H., de Schipper F.A., Snijders P.J. et al.: “HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis”. Obstet. Gynecol. Surv., 2004, 59, 543.

[12] Alonso I., Torné A., Puig-Tintoré L.M., Esteve R., Quinto L., Campo E. et al.: “Pre- and postconisation high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3”. Gynecol. Oncol., 2006, 103, 631.

[13] Bornstein J., Schwartz J., Perri A., Harroch J., Zarfati D.: “Tools for post LEEP surveillance”. Obstet. Gynecol. Surv., 2004, 59, 663.

[14] Bar-Am A., Gamzu R., Levin I, Fainaru O., Niv J., Almog B.: “Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up”. Gynecol. Oncol., 2003, 91, 149.

[15] Costa S., Sideri M., Syrjänen K., Terzano P., De Nuzzo M., De Simone P. et al.: “Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer”. Acta Cytol., 2000, 44, 310.

[16] Herrington C.S., Evans M.F., Hallam N.F., Charnock F.M., Gray W., McGee J.D.: “Human papillomavirus status in the prediction of high-grade cervical intraepithelial neoplasia in patients with persistent low-grade cervical cytological abnormalities”. Br. J. Cancer, 1995, 71, 206.

[17] Melchers W.J., Bakkers J.M., Wang J., de Wilde P.C., Boonstra H., Quint W.G. et al.: “Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evalua-tion and follow-up”. Am. J. Pathol., 1999, 155, 1473.

[18] Kulmala S.M., Syrjänen S., Shabalova I., Petrovichev N., Kozachenko V., Podistov J. et al.: “Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools”. J. Clin. Microbiol., 2004, 42, 2470.